antiquity
12-05-2002, 03:05 PM
Cognetix Announces Issuance of U.S. Patent on Contulakin-G to Treat Pain; First Clinical Safety Study Completed With CGX-1160
SALT LAKE CITY, Dec. 5 /PRNewswire/ -- Cognetix, Inc. announced today the issuance of United States patent number 6,489,298 by the U.S. Patent and Trademark Office. The patent covers the use of Contulakin-G (CGX-1160) for the treatment of acute and chronic pain, including pain from cancer, neuropathic pain and inflammatory chronic pain. Contulakin-G is a novel 16-amino acid conopeptide originally isolated from the venom of the marine snail Conus geographus.
This is the fourth patent in the Company's portfolio covering the composition and use in therapeutics of Contulakin-G, further broadening the proprietary position surrounding the compound. The patent portfolio of Cognetix is comprehensive, with an estate of more than 37 issued U.S. and international patents held by the Company under an exclusive license with the University of Utah Research Foundation. These patents collectively cover hundreds of conopeptides within 17 families, each targeting pharmaceutically important receptors and ion channels.
"We are excited about the potential of CGX-1160 to treat a broad range of pain syndromes, which is our major therapeutic and development focus," said Thomas B. King, Cognetix President and CEO. "Our goal in 2003 is to continue the aggressive development of the compound."
Cognetix recently completed an initial safety and pharmacokinetic human clinical study of CGX-1160 in healthy volunteers. A total of 48 individuals were studied, 36 receiving CGX-1160 and 12 receiving placebo, by intravenous administration. No serious adverse events were observed. In animal studies, CGX-1160 has been shown to be effective in models of acute, persistent, chronic inflammatory, post-surgical and neuropathic pain. CGX-1160 has exhibited a wide margin of safety in these animal models.
Cognetix is a privately-held biopharmaceutical company developing conopeptides, which are small peptide therapeutics derived from the venoms of Conus carnivorous marine snails. The Company's primary product development focus and expertise is in the field of pain. Conopeptides are known, however, to act on a wide variety of pharmaceutically relevant targets with extremely high potency and selectivity. Accordingly, the Company's research programs encompass a number of additional therapeutic areas. Research efforts at Cognetix are supported by a unique and proprietary technology platform that enables the accelerated discovery of novel conopeptides with preferred pharmacological properties, as well as their rapid and efficient synthetic manufacture.
SALT LAKE CITY, Dec. 5 /PRNewswire/ -- Cognetix, Inc. announced today the issuance of United States patent number 6,489,298 by the U.S. Patent and Trademark Office. The patent covers the use of Contulakin-G (CGX-1160) for the treatment of acute and chronic pain, including pain from cancer, neuropathic pain and inflammatory chronic pain. Contulakin-G is a novel 16-amino acid conopeptide originally isolated from the venom of the marine snail Conus geographus.
This is the fourth patent in the Company's portfolio covering the composition and use in therapeutics of Contulakin-G, further broadening the proprietary position surrounding the compound. The patent portfolio of Cognetix is comprehensive, with an estate of more than 37 issued U.S. and international patents held by the Company under an exclusive license with the University of Utah Research Foundation. These patents collectively cover hundreds of conopeptides within 17 families, each targeting pharmaceutically important receptors and ion channels.
"We are excited about the potential of CGX-1160 to treat a broad range of pain syndromes, which is our major therapeutic and development focus," said Thomas B. King, Cognetix President and CEO. "Our goal in 2003 is to continue the aggressive development of the compound."
Cognetix recently completed an initial safety and pharmacokinetic human clinical study of CGX-1160 in healthy volunteers. A total of 48 individuals were studied, 36 receiving CGX-1160 and 12 receiving placebo, by intravenous administration. No serious adverse events were observed. In animal studies, CGX-1160 has been shown to be effective in models of acute, persistent, chronic inflammatory, post-surgical and neuropathic pain. CGX-1160 has exhibited a wide margin of safety in these animal models.
Cognetix is a privately-held biopharmaceutical company developing conopeptides, which are small peptide therapeutics derived from the venoms of Conus carnivorous marine snails. The Company's primary product development focus and expertise is in the field of pain. Conopeptides are known, however, to act on a wide variety of pharmaceutically relevant targets with extremely high potency and selectivity. Accordingly, the Company's research programs encompass a number of additional therapeutic areas. Research efforts at Cognetix are supported by a unique and proprietary technology platform that enables the accelerated discovery of novel conopeptides with preferred pharmacological properties, as well as their rapid and efficient synthetic manufacture.